skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Estimate of Radiobiologic Parameters From Clinical Data for Biologically Based Treatment Planning for Liver Irradiation

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
; ;  [1]
  1. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI (United States)

Purpose: The Radiation Therapy Oncology Group (RTOG) is initiating a few new hypofractionation regimens (RTOG 0438) to treat liver cancer patients. To evaluate the radiobiologic equivalence between different regimens requires reliable radiobiologic parameters. The purpose of this work is to estimate a plausible set of such parameters for liver tumors and to design new optimized dose fractionation schemes to increase patient survival. Methods and Materials: A model was developed to fit clinical survival data from irradiation of a series of primary liver patients. The model consists of six parameters including radiosensitivity parameters {alpha} and {alpha}/{beta}, potential doubling time T{sub d}. Using this model together with the Lyman model for calculations of the normal tissue complication probability, we designed a series of hypofractionated treatment strategies for liver irradiation. Results: The radiobiologic parameters for liver tumors were estimated to be: {alpha}/{beta} = 15.0 {+-} 2.0 Gy, {alpha} = 0.010 {+-} 0.001 Gy {sup -1}, T{sub d} = 128 {+-} 12 day. By calculating the biologically effective dose using the obtained parameters, it is found that for liver patients with an effective liver volume of {approx}45% the dose fractionation regimens suggested in RTOG 0438 can be escalated to higher dose for improved patient survival ({approx}80% at 1 year) while keeping the normal tissue complication probability to less than 10%. Conclusions: A plausible set of radiobiologic parameters has been obtained based on clinical data. These parameters may be used for radiation treatment planning of liver tumors, in particular, for the design of new treatment regimens aimed at dose escalation.

OSTI ID:
21039806
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 70, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2007.10.037; PII: S0360-3016(07)04450-1; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Hypofractionation: What Does It Mean for Prostate Cancer Treatment?
Journal Article · Fri Jan 15 00:00:00 EST 2010 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039806

Hypofractionation Regimens for Stereotactic Radiotherapy for Large Brain Tumors
Journal Article · Wed Oct 01 00:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039806

Extrapolation of Normal Tissue Complication Probability for Different Fractionations in Liver Irradiation
Journal Article · Fri May 01 00:00:00 EDT 2009 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039806